Cited by 204Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

Open access
Bergeron, David, Gorno‐Tempini, Maria L., Rabinovici, Gil D., Santos‐Santos, Miguel A., Seeley, William, Miller, Bruce L., Pijnenburg, Yolande, Keulen, M. Antoinette +78 more·2018·Annals of Neurology

Abstract

Objective: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods: We conducted a meta‐analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid‐β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. Results: Amyloid‐β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001). Prevalence of amyloid‐β positivity increased with age in nfvPPA (from 10% at age 50 years to 27% at age 80 years, p < 0.01) and svPPA (from 6% at age 50 years to 32% at age 80 years, p < 0.001), but not in lvPPA (p = 0.94). Across PPA variants, ApoE ε4 carriers were more often amyloid‐β positive (58.0%) than noncarriers (35.0%, p < 0.001). Autopsy data revealed Alzheimer disease pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration–TDP‐43 in svPPA (80%), and frontotemporal lobar degeneration–TDP‐43/tau in nfvPPA (64%). Interpretation: This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid‐β biomarkers in PPA patients. Ann Neurol 2018;84:737–748

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.25333

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ADNC is observed not only in individuals with the typical, amnestic clinical presentation but also in people with atypical, non-amnestic presentations.

    “However, ADNC is observed not only in individuals with the typical, amnestic clinical presentation but also in people with atypical, non‐amnestic presentations.”

    From Automatic classification of AD pathology in FTD phenotypes using natural speech (2024) · cites this paper as [13]

    The Results (Autopsy Results in Distinct PPA Variants; page not provided) report primary AD pathology in patients with language-led, non-amnestic presentations, especially logopenic PPA. This supports the atypical-presentation part of the claim, but the paper does not assess people with typical amnestic presentations for comparison. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Alzheimer-type lesions are frequently observed as copathology in post-mortem examination of people who had other neurodegenerative diseases.

    “Alternatively, lesions of the Alzheimer type are frequently observed as copathology in post-mortem examination of people who had other neurodegenerative diseases.40,41,94,96”
  • Other phenotypes, including the behavioural variant or dysexecutive variant, the corticobasal variant, and other variants of primary progressive aphasia, are less commonly related to Alzheimer's disease pathology.

    “Other phenotypes, including the behavioural variant or dysexecutive variant,95,96 the corticobasal variant,97,98 and the other variants of primary progressive aphasia94,99 (appendix p 2), are less commonly related to Alzheimer’s disease pathology (uncommon Alzheimer’s disease phenotypes).”
  • In behavioural or dysexecutive variants, corticobasal syndrome, and semantic or non-fluent variants of primary progressive aphasia, positive Alzheimer's disease biomarkers are particularly ambiguous and can be considered either as Alzheimer's disease copathology or atypical forms of Alzheimer's disease.

    “This biomarker positivity is particularly ambiguous in the case of behavioural or dysexecutive variants, corticobasal syndrome, and semantic or non-fluent variants of primary progressive aphasia, in which the presence of positive Alzheimer’s disease biomarkers can be considered either as Alzheimer’s disease copathology or atypical forms of Alzheimer’s disease94,96,98,99 (appendix p 2).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bergeron, D., Gorno‐Tempini, M. L., Rabinovici, G. D., Santos‐Santos, M. A., Seeley, W., Miller, B. L., Pijnenburg, Y., Keulen, M. A., Groot, C., van Berckel, B. N. M., van der Flier, W. M., Scheltens, P., Rohrer, J. D., Warren, J. D., Schott, J. M., Fox, N. C., Sanchez‐Valle, R., Grau‐Rivera, O., Gelpi, E., Seelaar, H., Papma, J. M., van Swieten, J. C., Hodges, J. R., Leyton, C. E., Piguet, O., Rogalski, E. J., Mesulam, M. M., Koric, L., Kristensen, N., Pariente, J., Dickerson, B., Mackenzie, I. R., Hsiung, G. R., Belliard, S., Irwin, D. J., Wolk, D. A., Grossman, M., Jones, M., Harris, J., Mann, D., Snowden, J. S., Chrem‐Mendez, P., Calandri, I. L., Amengual, A. A., Miguet‐Alfonsi, C., Magnin, E., Magnani, G., Santangelo, R., Deramecourt, V., Pasquier, F., Mattsson, N., Nilsson, C., Hansson, O., Keith, J., Masellis, M., Black, S. E., Matías‐Guiu, J. A., Cabrera‐Martin, M., Paquet, C., Dumurgier, J., Teichmann, M., Sarazin, M., Bottlaender, M., Dubois, B., Rowe, C. C., Villemagne, V. L., Vandenberghe, R., Granadillo, E., Teng, E., Mendez, M., Meyer, P. T., Frings, L., Lleó, A., Blesa, R., Fortea, J., Seo, S. W., Diehl‐Schmid, J., Grimmer, T., Frederiksen, K. S., Sánchez‐Juan, P., Chételat, G., Jansen, W., Bouchard, R. W., Laforce, R. J., Visser, P. J., & Ossenkoppele, R.
Affiliations
  • Amsterdam Neuroscience (NL)
  • University of California, San Francisco (US)
  • Department of Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands
  • Alzheimer center Amsterdam Amsterdam UMC, Amsterdam Neuroscience, VU University Amsterdam the Netherlands
  • UCL Queen Square Institute of Neurology (GB)
  • Alzheimer's Disease and Other Cognitive Disorders Unit, August Pi i Sunyer Biomedical Research Institute Barcelona Spain
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
  • Erasmus MC (NL)
  • Alzheimer Center, Department of Neurology Erasmus University Medical Center Rotterdam the Netherlands
  • The University of Sydney (AU)
  • Harvard University (US)
  • Northwestern University (US)
  • Hôpital de la Timone (FR)
  • University of Toulouse, INSERM, Toulouse Neuroimaging Center Toulouse France
  • University of British Columbia (CA)
  • University of Pennsylvania (US)
  • University of Manchester (GB)
  • Center of Aging and Memory, Neurological Research Institute Buenos Aires Argentina
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Department of Neurology, CHRU Besançon and Integrative and Clinical Neurosciences Laboratory, Regional Memory Center University of Bourgogne Franche‐Comté Besançon France
  • Vita-Salute San Raffaele University (IT)
  • Inserm (FR)
  • Lund University (SE)
  • Sunnybrook Health Science Centre (CA)
  • Universidad Complutense de Madrid (ES)
  • Department of Neurology and Nuclear Medicine, San Carlos Clinical Hospital, San Carlos Health Research Institute Complutense University of Madrid Madrid Spain
  • Hôpital Fernand-Widal (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Université Paris-Sud (FR)
  • Pitié-Salpêtrière Hospital (FR)
  • The University of Melbourne (AU)
  • Universitair Ziekenhuis Leuven (BE)
  • University of California, Los Angeles (US)
  • VA West Los Angeles Medical Center (US)
  • University of Freiburg (DE)
  • Universitat Autònoma de Barcelona (ES)
  • Samsung Medical Center (KR)
  • Technical University of Munich (DE)
  • Department of Neurology Danish Dementia Research Center Copenhagen Denmark
  • Marqués de Valdecilla University Hospital (ES)
  • Maastricht University (NL)
  • Université Laval (CA)
  • Universitat Internacional de Catalunya (ES)
Corresponding author
Bergeron, David
Venue
Annals of Neurology
Publisher
Wiley
Published
2018-11
Volume
84
Issue
5
Pages
729-740
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2894273961
Cited by
203
References
75
Citations by year
2026: 20 · 2025: 29 · 2024: 25 · 2023: 24 · 2022: 33 · 2021: 32 · 2020: 28 · 2019: 12
FWCI
2.74
Type
journal article
Language
en
Open access
Locations
  • Annals of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • HAL (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
  • Lirias (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
primary progressive aphasia, amyloid-beta pathology, logopenic variant, semantic variant, APOE ε4, Alzheimer's disease, frontotemporal lobar degeneration, TDP-43, tau protein, amyloid PET, cerebrospinal fluid biomarkers, neuropathology, individual patient data
MeSH terms
Age Factors, Aged, Aged, 80 and over, Apolipoproteins E, Brain, Female, Genotype, Humans, Male, Middle Aged, Prevalence, Amyloid beta-Peptides, Aphasia, Primary Progressive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review